[go: up one dir, main page]

SI2945967T1 - Topen polipeptid receptorja fibroblastnega rastnega dejavnika 3 (FGR3) za uporabo v preprečevanju ali zdravljenju motenj zastoja rasti kosti - Google Patents

Topen polipeptid receptorja fibroblastnega rastnega dejavnika 3 (FGR3) za uporabo v preprečevanju ali zdravljenju motenj zastoja rasti kosti

Info

Publication number
SI2945967T1
SI2945967T1 SI201431607T SI201431607T SI2945967T1 SI 2945967 T1 SI2945967 T1 SI 2945967T1 SI 201431607 T SI201431607 T SI 201431607T SI 201431607 T SI201431607 T SI 201431607T SI 2945967 T1 SI2945967 T1 SI 2945967T1
Authority
SI
Slovenia
Prior art keywords
fgr3
polypeptide
prevention
treatment
factor receptor
Prior art date
Application number
SI201431607T
Other languages
English (en)
Inventor
Elvire Gouze
Original Assignee
Institut National De La Sante Et De La Recherche Medicale (Inserm)
Universite Paul Sabatier Toulouse Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National De La Sante Et De La Recherche Medicale (Inserm), Universite Paul Sabatier Toulouse Iii filed Critical Institut National De La Sante Et De La Recherche Medicale (Inserm)
Publication of SI2945967T1 publication Critical patent/SI2945967T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI201431607T 2013-01-16 2014-01-16 Topen polipeptid receptorja fibroblastnega rastnega dejavnika 3 (FGR3) za uporabo v preprečevanju ali zdravljenju motenj zastoja rasti kosti SI2945967T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2013/001480 WO2014111744A1 (en) 2013-01-16 2013-01-16 A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
PCT/EP2014/050800 WO2014111467A1 (en) 2013-01-16 2014-01-16 A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
EP14702206.5A EP2945967B1 (en) 2013-01-16 2014-01-16 A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders

Publications (1)

Publication Number Publication Date
SI2945967T1 true SI2945967T1 (sl) 2020-10-30

Family

ID=48289519

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201431607T SI2945967T1 (sl) 2013-01-16 2014-01-16 Topen polipeptid receptorja fibroblastnega rastnega dejavnika 3 (FGR3) za uporabo v preprečevanju ali zdravljenju motenj zastoja rasti kosti

Country Status (19)

Country Link
US (5) US20150344855A1 (sl)
EP (2) EP2945967B1 (sl)
JP (3) JP2016506914A (sl)
KR (3) KR20160002681A (sl)
CN (1) CN105121464B (sl)
AU (2) AU2013373679A1 (sl)
CA (2) CA2898415A1 (sl)
DK (1) DK2945967T3 (sl)
EA (2) EA201591324A1 (sl)
ES (1) ES2796743T3 (sl)
HU (1) HUE049556T2 (sl)
IL (2) IL239810A0 (sl)
MX (2) MX372787B (sl)
PE (1) PE20151664A1 (sl)
PL (1) PL2945967T3 (sl)
PT (1) PT2945967T (sl)
SG (2) SG11201505488XA (sl)
SI (1) SI2945967T1 (sl)
WO (2) WO2014111744A1 (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2898415A1 (en) 2013-01-16 2014-07-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
JP6948945B2 (ja) 2015-01-07 2021-10-13 ファイザー・インク 骨格成長障害を治療するための可溶性ｆｇｆｒ３デコイ
KR101894022B1 (ko) * 2016-04-25 2018-08-31 장부다 Vr 공간을 제공하는 디바이스를 이용한 결제 방법 및 그 디바이스
PL3481859T3 (pl) * 2016-07-07 2022-07-11 Pfizer Inc. Rozpuszczalne polipeptydy receptora 3 czynnika wzrostu fibroblastów (sfgfr3) i ich zastosowania
MX2020003114A (es) * 2017-09-20 2020-10-20 Pfizer Tratamiento de deposicion anormal de grasa visceral utilizando polipeptidos de receptor 3 de factor de crecimiento de fibroblastos soluble (sfgfr3).
CN108410803B (zh) * 2018-03-28 2019-02-05 湖南源品细胞生物科技有限公司 一种诱导脂肪干细胞成软骨分化的培养方法和培养液
CN110272900B (zh) * 2019-04-19 2024-03-26 中国人民解放军陆军军医大学 用于制备骨骼发育异常猪模型的sgRNA及其应用
WO2022106976A1 (en) 2020-11-18 2022-05-27 Pfizer Inc. Stable pharmaceutical formulations of soluble fgfr3 decoys
JP2022184798A (ja) 2021-06-01 2022-12-13 ファイザー・インク ｓＦＧＦＲ３ポリペプチドを生産するための細胞培養方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
EP1342476A3 (en) 1995-06-12 2003-09-17 Yeda Research And Development Co. Ltd. FGFR3 as a marker for mesenchymal skeletal progenitor cells and use of cytotoxic conjugates comprising an FGFR3 binding agent for the treatment of cartilagineous bony tumours
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
ATE309385T1 (de) 2000-06-28 2005-11-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
AU2002235202A1 (en) * 2000-12-18 2002-07-01 Gene Logic, Inc. Treatment of bone disorders by modulation of fgfr3
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
WO2002102973A2 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
BRPI0203172B8 (pt) * 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
JP2003104908A (ja) * 2001-09-28 2003-04-09 Ichikazu Nakao 軟骨無形成症治療剤
JP4252746B2 (ja) * 2001-10-05 2009-04-08 一和 中尾 軟骨無形成症治療剤
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
IL156495A0 (en) * 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
WO2005082096A2 (en) 2004-02-24 2005-09-09 Allergan, Inc. Botulinum toxin screening assays
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
EP2046384A4 (en) 2006-06-15 2009-12-02 Fibron Ltd ANTIBODIES BLOCKING FIBROBLAST GROWTH FACTOR RECEPTOR ACTIVATION AND METHODS OF USING THE SAME
WO2008038287A2 (en) 2006-09-28 2008-04-03 Hepacore Ltd. N-terminal fgf variants having increased receptor selectivity and uses thereof
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
WO2008133873A2 (en) * 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
EP2313435A4 (en) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
EP2318529B1 (en) 2008-08-04 2017-10-18 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
TWI381848B (zh) 2008-10-20 2013-01-11 Imclone Llc 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物
SG174904A1 (en) 2009-03-25 2011-11-28 Genentech Inc Anti-fgfr3 antibodies and methods using same
CN101585866B (zh) * 2009-07-02 2011-10-05 中国人民解放军第三军医大学野战外科研究所 调节fgfr3活性的多肽及其筛选方法和应用
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
EP2498799B1 (en) 2009-11-13 2016-08-17 Five Prime Therapeutics, Inc. Use of fgfr1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in fgfr2
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
JP2013517282A (ja) 2010-01-14 2013-05-16 イェール ユニバ−シティ− 受容体チロシンキナーゼ（ｒｔｋ）のインヒビターおよびその使用方法
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
WO2012088608A1 (en) * 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof
CN102219860B (zh) 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
MX342735B (es) 2011-10-24 2016-10-07 Halozyme Inc Diagnostico acompañante para terapia con agente anti-hialuronano y metodos de uso del mismo.
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
ES2932954T5 (en) 2012-07-24 2025-10-28 Univ Columbia Fgfr-tacc fusion proteins and methods thereof
RU2015102194A (ru) 2012-07-27 2016-09-20 Дженентек, Инк. Способы лечения связанных с fgfr3 состояний
AU2013337264B2 (en) 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
CA2898415A1 (en) 2013-01-16 2014-07-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
SI3097122T1 (sl) 2014-01-24 2020-07-31 Ngm Biopharmaceuticals, Inc. Protitelesa, ki se vežejo v domeni beta klotho 2, in metode za njihovo uporabo
JP6948945B2 (ja) 2015-01-07 2021-10-13 ファイザー・インク 骨格成長障害を治療するための可溶性ｆｇｆｒ３デコイ
PL3481859T3 (pl) 2016-07-07 2022-07-11 Pfizer Inc. Rozpuszczalne polipeptydy receptora 3 czynnika wzrostu fibroblastów (sfgfr3) i ich zastosowania
MX2020003114A (es) 2017-09-20 2020-10-20 Pfizer Tratamiento de deposicion anormal de grasa visceral utilizando polipeptidos de receptor 3 de factor de crecimiento de fibroblastos soluble (sfgfr3).

Also Published As

Publication number Publication date
EP2945967A1 (en) 2015-11-25
US10724014B2 (en) 2020-07-28
EA201591324A1 (ru) 2016-01-29
PE20151664A1 (es) 2015-11-28
WO2014111467A1 (en) 2014-07-24
US20210032608A1 (en) 2021-02-04
JP2016506914A (ja) 2016-03-07
MX2019013857A (es) 2020-01-20
CN105121464A (zh) 2015-12-02
MX372787B (es) 2020-07-03
PL2945967T3 (pl) 2020-11-16
MX2015009142A (es) 2015-11-06
KR102249454B1 (ko) 2021-05-07
JP2019107006A (ja) 2019-07-04
JP2016506912A (ja) 2016-03-07
KR20160002681A (ko) 2016-01-08
AU2014206844A1 (en) 2015-07-16
US11702642B2 (en) 2023-07-18
DK2945967T3 (da) 2020-07-13
SG11201505488XA (en) 2015-08-28
US20200199545A1 (en) 2020-06-25
US20150344855A1 (en) 2015-12-03
EP3736285A1 (en) 2020-11-11
KR20210054026A (ko) 2021-05-12
US11814654B2 (en) 2023-11-14
ES2796743T3 (es) 2020-11-30
HUE049556T2 (hu) 2020-09-28
US20150353624A1 (en) 2015-12-10
EP2945967B1 (en) 2020-04-15
IL239996A0 (en) 2015-08-31
CA2896978A1 (en) 2014-07-24
EA201591055A1 (ru) 2016-04-29
CA2898415A1 (en) 2014-07-24
HK1217959A1 (zh) 2017-01-27
KR20150122136A (ko) 2015-10-30
PT2945967T (pt) 2020-05-28
AU2013373679A1 (en) 2015-08-13
IL239810A0 (en) 2015-08-31
JP6995069B2 (ja) 2022-02-04
CN105121464B (zh) 2021-05-07
US20210032607A1 (en) 2021-02-04
WO2014111744A1 (en) 2014-07-24
SG11201505140XA (en) 2015-07-30

Similar Documents

Publication Publication Date Title
IL239810A0 (en) Soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
PL2968218T3 (pl) Skojarzenie do leczenia choroby parkinsona
PT3811943T (pt) Composto para uso no tratamento de distúrbios oculares
IL245101B (en) Derivatives of 1,4-cyclohexylamine and processes for their preparation
LT3481846T (lt) 11-pakeistieji 24-hidroksisteroliai, skirti naudoti gydant su nmda susijusias būkles
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
ZA201501677B (en) Mglu2/3 antagonists for the treatment of autistic disorders
SI2945642T1 (sl) Protein faktorja 1 za uporabo pri zdravljenju ali preprečevanju bolezni
PT3302454T (pt) Composições para utilização no tratamento da doença de parkinson e distúrbios associados
PT3160464T (pt) 6-hidroxibuspirona para uso no tratamento de transtornos do movimento
SI3049100T1 (sl) Modificirani faktorji rasti fibroblasta-1 za zdravljenje očesnih motenj
IL248855B (en) S-pyralindole and its pharmaceutically acceptable salts for use in medicine
GB2589744B (en) Geoengineering constructions for use in railways
IL254766A0 (en) A certain analog of trifluoroethyl quinoline for use in the treatment of Sjögren's syndrome
IL254450A0 (en) A preparation for use in the treatment of dislocated vertebrae
GB201513556D0 (en) Patch for person's skin
EP3648789C0 (en) MTMR2-S POLYPEPTIDE FOR USE IN THE TREATMENT OF MYOPATHY
GB201521442D0 (en) Polytpeptides and analogues thereof for use in the treatment of diabetes and bone disorders